Homburger advised Noema Pharma AG on its Series B extension financing round
On December 11, 2024, Noema Pharma AG announced that it has successfully closed a Series B extension financing round with an investment from EQT Life Sciences,
Homburger advised the shareholders of MIV Asset Management AG on the sale of 100% of their shares to Bank J. Safra Sarasin AG
On December 2, 2024, Bank J. Safra Sarasin AG announced the acquisition of 100% of the shares of MIV Asset Management AG (“MIV”).
Homburger advises EQT on the sale of 6.73% of Galderma’s share capital via an accelerated bookbuilding process
On November 20, 2024, Sunshine SwissCo AG (a consortium led by EQT), the Abu Dhabi Investment Authority (ADIA) and Auba Investment Pte. Ltd. (all acting as the Sellers)
Homburger advised Alchemy US Holdco 1 LLC on the refinancing of its term loan and ABL credit agreements
In July 2024, Alchemy US Holdco 1, LLC renewed its credit financings and entered into a term loan credit agreement with HPS Investment Partners,
Homburger advises SIX Group AG in connection with the contemplated acquisition of Aquis Exchange Plc
Homburger acts as counsel to SIX Group AG in connection with the contemplated acquisition of Aquis Exchange Plc, which was announced on November 11, 2024.
Homburger advised Raiffeisen Schweiz Genossenschaft in the issuance of CHF 150 m 1.350 per cent. bonds due 2029 by Viseca Payment Services AG
On October 30, 2024, Viseca Payment Services AG successfully completed its issuance of CHF 150 m 1.350 per cent. bonds due 2029.
Homburger advised the Kellenberger family on the reduction of its shareholding in Calida Holding AG
The Kellenberger family has significantly reduced its shareholding in Calida Holding AG (the Company) in two transactions, a public buy-back offer and a direct repurchase.
Homburger advised UBS Switzerland AG and other syndicate banks in connection with the financing of the acquisition of IMPAG
Homburger acted as counsel to UBS Switzerland AG as mandated lead arranger, underwriter, agent,
Homburger advised Elanco International, Inc. on its incremental term facility
On August 13, 2024, Elanco Animal Health Incorporated and Elanco US Inc. entered into an incremental assumption agreement to obtain an incremental term facility.
Homburger advised Molecular Partners AG in connection with its USD 20 m Underwritten Offering of American Depositary Shares
On October 25, 2024, Molecular Partners AG, a clinical-stage biotech company developing a new class of custom-built protein drugs known